Cargando…

Avelumab vs Standard Second-Line Chemotherapy in Patients With Metastatic Colorectal Cancer and Microsatellite Instability: A Randomized Clinical Trial

IMPORTANCE: Only 1 randomized clinical trial has shown the superiority of immune checkpoint inhibitors in patients with deficient mismatch repair and/or microsatellite instability (dMMR/MSI) metastatic colorectal cancer (mCRC) in the first-line setting. OBJECTIVES: To determine whether avelumab (an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taïeb, Julien, Bouche, Olivier, André, Thierry, Le Malicot, Karine, Laurent-Puig, Pierre, Bez, Jérémie, Toullec, Clémence, Borg, Christophe, Randrian, Violaine, Evesque, Ludovic, Corbinais, Stéphane, Perrier, Hervé, Buecher, Bruno, Di Fiore, Frederic, Gallois, Claire, Emile, Jean Francois, Lepage, Côme, Elhajbi, Farid, Tougeron, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2023
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401392/ https://www.ncbi.nlm.nih.gov/pubmed/37535388 http://dx.doi.org/10.1001/jamaoncol.2023.2761

Ejemplares similares

Microsatellite Instability in Colorectal Cancers: Carcinogenesis, Neo-Antigens, Immuno-Resistance and Emerging Therapies
por: Randrian, Violaine, et al.
Publicado: (2021)

Microsatellite Instability: Diagnosis, Heterogeneity, Discordance, and Clinical Impact in Colorectal Cancer
por: Evrard, Camille, et al.
Publicado: (2019)

Safety of FOLFIRI + Durvalumab +/− Tremelimumab in Second Line of Patients with Advanced Gastric Cancer: A Safety Run-In from the Randomized Phase II Study DURIGAST PRODIGE 59
por: Evrard, Camille, et al.
Publicado: (2022)

Efficacy of donepezil for the treatment of oxaliplatin-induced peripheral neuropathy: DONEPEZOX, a protocol of a proof of concept, randomised, triple-blinded and multicentre trial
por: Kerckhove, Nicolas, et al.
Publicado: (2022)

Impact of G-CSF Prophylaxis on Chemotherapy Dose-Intensity, Link Between Dose-Intensity and Survival in Patients with Metastatic Pancreatic Adenocarcinoma
por: Canton, Clémence, et al.
Publicado: (2022)

Endoscopy to Diagnose and Prevent Digestive Cancers in Lynch Syndrome
por: Olivier, Raphael, et al.
Publicado: (2021)

HSP110 as a Diagnostic but Not a Prognostic Biomarker in Colorectal Cancer With Microsatellite Instability
por: Tachon, Gaelle, et al.
Publicado: (2022)

Construction of quality of life change patterns: example in oncology in a phase III therapeutic trial (FFCD 0307)
por: Nuemi, Gillles, et al.
Publicado: (2015)

Artificial intelligence-guided tissue analysis combined with immune infiltrate assessment predicts stage III colon cancer outcomes in PETACC08 study
por: Reichling, Cynthia, et al.
Publicado: (2020)

Hepatic Arterial Infusion Chemotherapy With Folfirinox or Oxaliplatin Alone in Metastatic Colorectal Cancer
por: Randrian, Violaine, et al.
Publicado: (2022)

Avelumab in newly diagnosed glioblastoma
por: Jacques, Francois H, et al.
Publicado: (2021)

New Artificial Intelligence Score and Immune Infiltrates as Prognostic Factors in Colorectal Cancer With Brain Metastases
por: Randrian, Violaine, et al.
Publicado: (2021)

Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer
por: Marisa, Laetitia, et al.
Publicado: (2021)

Postoperative circulating tumor DNA detection is associated with the risk of recurrence in patients resected for a stage II colorectal cancer
por: Grancher, Adrien, et al.
Publicado: (2022)

Heterogeneity of Mismatch Repair Status and Microsatellite Instability between Primary Tumour and Metastasis and Its Implications for Immunotherapy in Colorectal Cancers
por: Evrard, Camille, et al.
Publicado: (2022)

Management of digestive cancers during the COVID-19 second wave: A French intergroup point of view (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFR)
por: Tougeron, David, et al.
Publicado: (2021)

Avelumab demonstrates promise in advanced NSCLC
por: Marciscano, Ariel E., et al.
Publicado: (2017)

Evaluation of the potential for QTc prolongation with avelumab
por: Vugmeyster, Yulia, et al.
Publicado: (2019)

Discordance between immunochemistry of mismatch repair proteins and molecular testing of microsatellite instability in colorectal cancer
por: Guyot D'Asnières De Salins, A., et al.
Publicado: (2021)

Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300
por: Bang, Y -J, et al.
Publicado: (2018)

Immunotherapy in Merkel cell carcinoma: role of Avelumab
por: Palla, Amruth R, et al.
Publicado: (2018)

Diffuse Alveolar Hemorrhage With Avelumab Maintenance Therapy
por: Li, Si, et al.
Publicado: (2021)

Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial
por: Aparicio, Thomas, et al.
Publicado: (2020)

A Phase II Study of Avelumab Monotherapy in Patients with Mismatch Repair–Deficient/Microsatellite Instability–High or POLE-Mutated Metastatic or Unresectable Colorectal Cancer
por: Kim, Jwa Hoon, et al.
Publicado: (2020)

Efficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in first-line treatment of advanced gastric signet ring cell carcinoma: an AGEO multicentre study
por: Pernot, Simon, et al.
Publicado: (2018)

Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma
por: Bullement, Ash, et al.
Publicado: (2019)

Avelumab-induced Pneumonitis in Metastatic Merkel Cell Carcinoma
por: Morimoto, Toshiki, et al.
Publicado: (2022)

Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study
por: Pernot, Simon, et al.
Publicado: (2020)

PIK3CA mutations predict recurrence in localized microsatellite stable colon cancer
por: Manceau, Gilles, et al.
Publicado: (2015)

Adjuvant Chemotherapy for Stage III Colon Cancer
por: Taieb, Julien, et al.
Publicado: (2020)

A review of avelumab in locally advanced and metastatic bladder cancer
por: Rao, Arpit, et al.
Publicado: (2019)

Product review: avelumab, an anti-PD-L1 antibody
por: Collins, Julie M., et al.
Publicado: (2018)

Re-Induction of Avelumab for Patients with Metastatic Merkel Cell Carcinoma
por: Hiroyuki, Goto, et al.
Publicado: (2023)

Evaluation of the relevance of the growth modulation index (GMI) from the FFCD 0307 randomized phase III trial comparing the sequence of two chemotherapeutic regimens
por: du Rusquec, P., et al.
Publicado: (2023)

Avelumab inducing hypothyroidism and hypoadrenalism: A case report and review of literature
por: Aziz, Kashif, et al.
Publicado: (2018)

Efficacy and immune-related adverse event associations in avelumab-treated patients
por: Kelly, Karen, et al.
Publicado: (2020)

Survival Analysis in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab
por: Lanitis, Tereza, et al.
Publicado: (2019)

Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma
por: Glutsch, Valerie, et al.
Publicado: (2021)

Avelumab plus axitinib vs. sunitinib for advanced renal-cell carcinoma
por: Zhang, Yue, et al.
Publicado: (2019)

Avelumab Dose Selection for Clinical Studies in Pediatric Patients with Solid Tumors
por: Vugmeyster, Yulia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nrcpd9p8h0lekkhjolcclges96